Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

Showing results filtered by:
Clear All
Emerging Infectious Diseases/Pathogens
Infectious Diseases
Plague

21 Results

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The National Emerging Infectious Diseases Laboratories (NEIDL) is one of two National Biocontainment Laboratories constructed under a grant from the National Institute of Allergy and Infectious Diseases.

The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories. The Center provides a safe, secure, state of art facility for university investigators, government scientists and industry representatives to collaboratively research bacteria and viruses that cause human and animal diseases

An overview of the NIAID-supported Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) at The Duke University School of Medicine.

George Mason University's Biomedical Research Laboratory (BRL) is one of the NIAID supported Regional Biocontainment Laboratories. It operates as a central core facility in the Institute for Biohealth Innovation to advance research and develop novel diagnostics, therapeutics, and vaccines against viral and bacterial infectious agents by a diverse population of investigators.

The Rutgers University Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories. The RBL is a highly secure facility designed to provide an ultra-safe work environment for scientists and support staff, as well as the public at large.

The Tufts New England Regional Biosafety Laboratory (RBL) is one of the NIAID-supported Regional Biocontainment Laboratories. The RBL is a 41,000 square foot resource available to researchers in industry, academia, government and not-for-profit, dedicated to the study of existing and emerging infectious diseases, toxin-mediated diseases and medical countermeasures important to biodefense.

The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories. The Lab provides a valuable national resource and asset to the University of Louisville, our region, and the greater scientific and public health communities. The Lab has been built to the most stringent federal standards

The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.

As one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the Galveston National Laboratory (GNL) enables progress in our understanding of the fundamental mechanisms underlying the spread of infectious diseases and the pathogenesis of the diseases they cause.

The Chicago Center for Functional Annotation (CCFA) is defining gene function on multiple scales, using a multi-disciplinary set of cellular, genetic, molecular, and biochemical approaches. The primary goal of the CCFA is to define the biochemical and cellular functions of uncharacterized genes in the NIAID priority pathogens, Yersinia pestis and Brucella abortus.

The GCID use and develop or improve innovative applications of genomic technologies, such as RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes. Multiple strains and isolates of specific microbial species, populations and communities have been and continue to be sequenced.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

The ICSSC provides a wide range of support services to clinical investigators who are conducting international research funded by the Division of Microbiology and Infectious Diseases (DMID), including consultation and assistance to investigators for protocol development, site assessment, data management, case report form (CRF) development, biostatistics and trainings.

The Interventional Agent Development Services program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious disease-causing pathogens and/or toxins.

Note: Devices are excluded.

Part of the Therapeutic Development Services program.

The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclonal antibodies, against viral (other than HIV), bacterial, parasitic, and fungal pathogens, includin

This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

The Structural Genomics Centers for Infectious Diseases provide the research community with: 3-D protein structures and protein-ligand complexes; Sequence-verified clones and peptides; Services that deliver requested 3-D structure determination; and Molecular screening of proteins in complex with inhibitors, cofactors and substrate analogs

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).